UBS Group
MXCT icon

UBS Group’s MaxCyte MXCT Stock Holding History

UBS Group’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Buy
284,273
+13,219
+5% +$13.2K ﹤0.01% 6452
2026
Q1 		$191K Buy
271,054
+146,463
+118% +$137K ﹤0.01% 6666
2025
Q4 		$193K Sell
124,591
-349,896
-74% -$559K ﹤0.01% 6598
2025
Q3 		$750K Buy
474,487
+308,769
+186% +$537K ﹤0.01% 5794
2025
Q2 		$361K Sell
165,718
-37,569
-18% -$91K ﹤0.01% 6276
2025
Q1 		$555K Buy
203,287
+92,641
+84% +$365K ﹤0.01% 5765
2024
Q4 		$460K Buy
110,646
+42,595
+63% +$161K ﹤0.01% 5903
2024
Q3 		$265K Buy
68,051
+18,449
+37% +$77.7K ﹤0.01% 5669
2024
Q2 		$194K Sell
49,602
-46,830
-49% -$201K ﹤0.01% 5676
2024
Q1 		$404K Buy
96,432
+858
+0.9% +$4.03K ﹤0.01% 5367
2023
Q4 		$449K Buy
95,574
+30,643
+47% +$119K ﹤0.01% 5186
2023
Q3 		$203K Sell
64,931
-5,986
-8% -$24.1K ﹤0.01% 5373
2023
Q2 		$326K Buy
70,917
+18,862
+36% +$86.7K ﹤0.01% 5157
2023
Q1 		$258K Buy
52,055
+8,346
+19% +$41.1K ﹤0.01% 5201
2022
Q4 		$239K Buy
43,709
+32,770
+300% +$201K ﹤0.01% 5314
2022
Q3 		$71K Sell
10,939
-8,364
-43% -$46.7K ﹤0.01% 6025
2022
Q2 		$91K Buy
19,303
+16,480
+584% +$81.2K ﹤0.01% 5503
2022
Q1 		$20K Sell
2,823
-40,892
-94% -$279K ﹤0.01% 7450
2021
Q4 		$445K Buy
43,715
+34,481
+373% +$370K ﹤0.01% 5071
2021
Q3 		$113K Buy
+9,234
New +$139K ﹤0.01% 5752

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

UBS Group's MXCT Position: Q2 2026 in Review

UBS Group increased its MaxCyte (MXCT) stake by 4.9% in Q2 2026, buying an estimated $13.2K and bringing the position to 284,273 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #6452.

UBS Group first reported a position in MXCT in Q3 2021 and has held it in 20 quarters since. The position peaked at $750K in Q3 2025. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • UBS Group held 284,273 shares of MaxCyte worth $350K as of Q2 2026.
  • UBS Group bought 13,219 MaxCyte shares in Q2 2026, an estimated $13.2K.
  • MaxCyte made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6452 holding.
  • UBS Group first reported a position in MaxCyte in Q3 2021 and has held it in 20 quarters since.
  • UBS Group's MaxCyte position peaked at $750K in Q3 2025.
  • 122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.